Paul qualified in medicine and after 10 years in cardiology in the NHS, joined the pharmaceutical industry, with experience in clinical trial operations, medical affairs and patient engagement. He represents MSD in PARADIGM, a pan European project to make patient engagement in clinical development the norm. He continues to practice medicine and is a member of the NICE committee that decides whether new medicines should be paid for by the NHS in England.